Menu
EMAHSN
QbTest childA pioneering project to spread the use of an innovative computerised test to support the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) has received on-going funding from three community health NHS trusts in the East Midlands region.

The Trusts’ commitment to mainstreaming the use of QbTest - an innovative computerised test for Attention Deficit Hyperactivity Disorder (ADHD) - follows a successful 12 month demonstrator project funded by the East Midlands Academic Health Science Network (EMAHSN).

The EMAHSN worked with international medical technology company Qbtech Ltd to roll out QbTest - the only CE marked, EMA registered and Food and Drug Administration (FDA) cleared intervention that measures attention, impulsivity and motor activity all at the same time. These indicators are core symptoms of ADHD and accurate measurement adds objectivity to support timely diagnosis.

The demonstration services followed a multicentre RCT trial by the Collaboration for Leadership in Applied Health Research and Care East Midlands (CLAHRC) confirmed the effectiveness of QbTest (www.clahrc-em.nihr.ac.uk/research/aqua-trial).

The pilot project was initially rolled out during 2017 at seven sites across Derbyshire, Leicestershire and Lincolnshire. United Lincolnshire Hospitals NHS Trust, Derbyshire Healthcare NHS Foundation Trust and Leicestershire Partnership NHS Trust have now agreed to continue funding the provision of the QbTest for young patients and their families. Evaluation of the project has identified up to 22% cost savings and effectiveness in reducing time to diagnosis by an average of 145 days. *

ADHD begins in childhood and often persists into adult life. Latest statistics from the Centre of Mental Health suggest that around 1.5% of young people aged 5-16 years have ADHD and it is though around 12,000 young people in the East Midlands have the condition. Public Health England estimates that the number of people aged 16-24 in the region with ADHD is even higher - more than 76,000.

As well as impacting on a young person’s wellbeing and development through reduced ability to concentrate and control behaviour, the condition also is estimated to cost to the health, care and education system around £12m per year.

Over the last ten years there has been a six-fold increase in the prevalence and rate of medication prescriptions for ADHD in the UK. Assessment and diagnosis is usually based on subjective clinical observation, interviews and observer questionnaire reports.

The EMAHSN and Qbtech’s collaboration with the East Midlands Trusts aimed to transform care within the region by using the computerised system - alongside traditional observation and interviews – to improve diagnosis and deliver significant savings to the NHS. This has been achieved through a reduction in the number of appointments needed for diagnosis and by ruling out ADHD sooner for ambiguous cases. Objective computerised systems - like QbTest – also have the potential to improve the experience of care for patients and their families who receive speedier diagnosis and appropriate treatment at the earliest opportunity.

Chris Hart, Commercial Director at the EMAHSN said: “This is a fantastic example of partnership working across the NHS and technology industry to bring real benefits to patients and add value to the health and care system.”

“The adoption and spread of innovation is fundamental to the future sustainability of the NHS and we are delighted to see mainstream funding provided in three areas to secure the continuation of QbTest.”

Dr Julie Clarke, Consultant Paediatrician at United Lincolnshire Hospitals and Clinical Lead for the project said, “As a clinician with extensive experience in assessment, diagnosis and treatment of ADHD, I can honestly say that the addition of QbTesting has revolutionised my clinical practice. The feedback from clinicians, parents and schools so far has all been extremely positive. We are already planning how we can extend the use of QbTests into other areas.”

Fran Guerra, Neurodevelopmental nurse specialist at Leicestershire Partnership NHS Trust

said: “The QbTest provides an up to date platform to test and observe young people and gain meaningful data, which can be easily interpreted to support the diagnostic process. It helps to reduce clinical observation time, supporting an overall reduction in time for the diagnostic process. The QbTest also supports ongoing monitoring and efficacy of the use of medications, which is a huge help.”

Donna Whitemore, Team Manager of the Neurodevelopmental Service at Derbyshire Healthcare NHS Foundation Trust, said: “We know it’s important for families to get advice and support as quickly as possible when a child is thought to have ADHD. Having a computerised tool like QbTest is contributing to effective medications management and helping to reduce the time to diagnosis, which in turn alleviates families’ uncertainty.”

Tony Doyle, Managing Director of Qbtech commented, “The support of the EMAHSN and the skilled clinicians who have been fundamental to this project has allowed us to demonstrate the impact and value of QbTest, both for patients and the NHS.

“We are delighted that our technology will continue to be used across these sites. We believe that the independent evaluation from the EMAHSN showing up to 22% cost savings and reduced waits for diagnosis will compel many other Trusts and CCGs to adopt QbTest to benefit their patients.”

-ends-

Notes to editors

* Evaluation results

Reduction in time to diagnosis for each of the three project areas was as follows:

· Derbyshire: reduced by 166 days (approx. 5.5 months)

· Leicestershire: reduced by 153 days (approx. 5 months)

· Lincolnshire: reduced by 117 days (approx. 4 months)

Average 16.6% cost saving across the three trusts with individual cost savings in each of the three areas as follows:

· Derbyshire: 22% cost reduction (provisional calculation TBC)

· Leicestershire: 18% cost reduction

· Lincolnshire: 10% cost reduction

About the East Midlands Academic Health Science Network (EMAHSN)

EMAHSN is one of 15 Academic Health Science Networks in England. EMAHSN brings together NHS organisations, universities, industry and social care to transform the health of the region’s 4.6m residents and stimulate wealth.

Current priorities focus on support Sustainability and Transformation Partnerships, with projects more than 20 innovation projects focusing on challenges including cancer, diabetes, mental health, atrial fibrillation and liver disease.

In July 2017, NHS England confirmed that the 15 AHSNs will be relicensed for a further five years from April 2018, as the key innovation arm of the NHS.

EMAHSN enquiries: Sarah Hewitt

0115 748 4243, This email address is being protected from spambots. You need JavaScript enabled to view it.  | @EM_AHSN | www.emahsn.org.uk 

About Qbtech

- Qbtech provide cleared ADHD Tests to NHS clinics (QbTest) and schools (QbCheck)

- QbTest is an ADHD Testing system with an infra-red motion capture camera and a computerised test of sustained attention. It shortens assessment so treatment can be given earlier, improves the confidence of specialists to rule in and rule out ADHD whilst improving communication between doctors, parents and schools. More information: https://www.qbtech.com/qbtest

Qbtech Limited enquiries: Tony Doyle, 07771937845, This email address is being protected from spambots. You need JavaScript enabled to view it.